Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 5 of 7, showing 10 Applications out of 69 total, starting on record 41, ending on 50

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

41.

ECCT/25/12/02   ITU512 Study - Site 6003
    A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease   
Principal Investigator(s)
1. Godfrey Allan Otieno
Site(s) in Kenya
1. Site 6001: International Cancer Institute (Uasin Gishu county)
2. Site 6002: Gertrude’s Children’s Hospital (Nairobi City county)
3. Site 6003: KEMRI Kondele Children’s Hospital (Kisumu county)
 
23-10-2026 View

42.

ECCT/13/07/01   HIVCORE004/N004
    A phase I/IIa clinical trial of universal HIV-1 vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and ChAdV63.HIVconsv in combined regimens in healthy HIV-1/2-negative adults in Nairobi.   
Principal Investigator(s)
1. Prof. Walter Godfrey Jaoko
Site(s) in Kenya
KAVI-KANGEMI RESEARCH SITE
 
19-06-2013 View

43.

ECCT/20/05/01   ChAdOx1 nCoV-19 trial
    A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya   
Principal Investigator(s)
1. George Warimwe
Site(s) in Kenya
KEMRI-CGMRC
 
08-09-2020 View

44.

ECCT/19/05/01   A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults
    A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
KAVI-ICR KNH SITE
 
08-07-2019 View

45.

ECCT/17/05/04   Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost
    A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI WALTER REED KERICHO
 
07-07-2017 View

46.

ECCT/24/08/01   Evaluate clearance of HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Kevin Makori Gesimba
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Victoria Cancer Care and Research centre (Nyamira county)
 
16-10-2024 View

47.

ECCT/25/02/04   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. CREA-N Machakos Level 5 Hospital Site (Machakos county)
 
06-03-2025 View

48.

ECCT/25/02/05   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Irene Diana Odhiambo
Site(s) in Kenya
1. Victoria Biomedical Research Institute, Kisumu County Referral Hospital (Kisumu county)
 
07-03-2025 View

49.

ECCT/25/02/07   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI-RCTP (Kisumu county)
 
13-03-2025 View

50.

ECCT/25/02/06   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
06-03-2025 View